

## DAFTAR PUSTAKA

- Afkari, H., Makrufardi, F., Hidayat, B., Budiawan H. 2021. *Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study*. *Annals of Medicine and Surgery*, 67: 1-5
- American Cancer Society. (2016). *Bone Metastasis*. Georgia, US: American Cancer Society
- American Cancer Society. 2019. 'Breast cancer'. In: *Breast cancer facts & figures 2019-2020*. Atlanta: American Cancer Society, Inc. pp. 1–32.
- Anggorowati, L. (2013). Faktor Risiko Kanker Payudara Wanita. *Jurnal Kesehatan Masyarakat*, 8(2), 121–126.
- Barnes, G. L., Hebert, K. E., Kamal, M., Javed, A., Einhorn, T. A., Lian, J. B., Stein, G. S., & Gerstenfeld, L. C. (2004). Fidelity of Runx2 Activity in Breast Cancer Cells Is Required for the Generation of Metastases-Associated Osteolytic Disease. *Cancer Research*, 64(13), 4506–4513. <https://doi.org/10.1158/0008-5472.CAN-03-3851>
- Bray, F., Ferlay, J. & Soerjomataram, I. 2018. *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA: A Cancer Journal for Clinicians, 68: 394–424. . <https://doi.org/10.3322/caac.21492>
- Brook, N., Brook, E., Dharmarajan, A., Dass, C. R., Chas, A. 2018. *Breast cancer bone metastasis: pathogenesis and therapeutic targets*. Elsevier book Press. pp. 63-78
- Caldeira, P. R. de-A. F., Martinez, C. A. R., & Caldeira, J. R. F. (2019). Evaluation of bone metastasis of breast cancer to long or short bones, according to molecular subtypes: retrospective study. *Mastology*, 29(1), 32–36. <https://doi.org/10.29289/2594539420190000436>
- Chang, J., Clark, G. M., Allred, D. C., Mohsin, S., Chamness, G., & Elledge, R. M. (2003). Survival of patients with metastatic breast carcinoma. *Cancer*, 97(3), 545–553. <https://doi.org/10.1002/cncr.11083>
- Chen, Y.-C., Sosnoski, D. M., & Mastro, A. M. (2010). Breast cancer metastasis to the bone: mechanisms of bone loss. *Breast Cancer Research*, 12(6), 215. <https://doi.org/10.1186/bcr2781>
- Chiechi, A., Waning, D. L., Stayrook, K. R., Buijs, J. T., Guise, T. A., & Mohammad, K. S. (2013). Role of TGF- $\beta$  in breast cancer bone metastases. *Advances in Bioscience and Biotechnology*, 04(10), 15–30. <https://doi.org/10.4236/abb.2013.410A4003>

- Cook, G. J., Houston, S., Rubens, R., Maissey, M. N., & Fogelman, I. (1998). Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. *Journal of Clinical Oncology*, 16(10), 3375–3379. <https://doi.org/10.1200/JCO.1998.16.10.3375>
- Cook, J.R., Gurdip, K., Azad, Vicky, G. 2016. *Imaging Bone Metastases in Breast Cancer: Staging and Response Assesment*. Imaging Bone Metastases, pp. 1-7.
- Cleeland, C., et al. 2018. *Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer Support*. Care Cancer, 24 (8): 3557-3565. doi: 10.1007/s00520-016-3154-x
- Cuello-López, J., Fidalgo-Zapata, A., López-Agudelo, L., & Vásquez-Trespalcios, E. (2018). Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. *PLOS ONE*, 13(11), e0207224. <https://doi.org/10.1371/journal.pone.0207224>
- Dagenais, M., Dupaul-Chicoine, J., Douglas, T., Champagne, C., Morizot, A., & Saleh, M. (2017). The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. *OncoImmunology*, 6(3), e1287247 (1-11). <https://doi.org/10.1080/2162402X.2017.1287247>
- Day, K. C., Hiles, G. L., Kozminsky, M., Dawsey, S. J., Paul, A., Brose, L. J., Shah, R., Kunja, L. P., Hall, C., Palanisamy, N., Daignault-Newton, S., El-Sawy, L., Wilson, S. J., Chou, A., Ignatoski, K. W., Keller, E., Thomas, D., Nagrath, S., Morgan, T., & Day, M. L. (2017). HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. *Cancer Research*, 77(1), 74–85. <https://doi.org/10.1158/0008-5472.CAN-16-1656>.
- Dewi, D. A. K., Wiratnaya, G. E., & Setiawan, G. B. (2019). Prevalensi Metastatic Bone Disease (MBD) Berdasarkan Umur, Lokasi, dan Tumor Primer di RSUP Sanglah/FK Unud Periode 2013-2017. *JURNAL MEDIKA UDAYANA*, 8(8), 1–6.
- Djuita, F., & Defrizal. (2007). *Radiasi pada Metastasis Tulang*. Indonesian Journal of Cancer, 4: 135–139.
- El-Feky, M., & Jones, J. (2010). Breast cancer metastases. In *Radiopaedia.org*. Radiopaedia.org. <https://doi.org/10.53347/rID-9026>
- Ellmann S., Beck M., Kuwert T., Uder M., bauerle T., Juni 2015. *Multimodal imaging of bone metastases: From preclinical to clinical applications*. Elsevier Academic Press, pp. 1-12.
- Farooqi, A. A., & Siddik, Z. H. (2015). Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. *Cell*

- Biochemistry and Function*, 33(5), 257–265. <https://doi.org/10.1002/cbf.3120>
- Gong, Y., Liu, Y. R., Ji, P., Hu, X., & Shao, Z. M. (2017). Impact of molecular subtypes on metastatic breast cancer patients: A SEER population-based study. *Scientific Reports*, 7(January), 1–10. <https://doi.org/10.1038/srep45411>
- Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A. M., Fasola, G., & Puglisi, F. 2015. *Pattern of metastasis and outcome in patients with breast cancer*. *Clinical & Experimental Metastasis*, 32(2): 125–133. <https://doi.org/10.1007/s10585-015-9697-2>
- Globocan. 2017. *International Agency for Research on Cancer 2017*. <https://gco.iarc.fr>
- Gregory, L. S., Choi, W., Burke, L., & Clements, J. A. (2013). Breast Cancer Cells Induce Osteolytic Bone Lesions In vivo through a Reduction in Osteoblast Activity in Mice. *PLoS ONE*, 8(9), e68103. <https://doi.org/10.1371/journal.pone.0068103>
- Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., & Ueno, N. T. (2004). Bone Imaging in Metastatic Breast Cancer. *Journal of Clinical Oncology*, 22(14), 2942–2953. <https://doi.org/10.1200/JCO.2004.08.181>
- Hidayat, A. 2012. *Jenis Uji Korelasi: Pearson, Spearman-rho, Kendall-Tau, Gamma dan Somers*. [Online] on Statistikian <https://www.statistikian.com/2012/07/pearson-spearman-rho-kendall-tau-gamma-dan-somers.html> (Accessed August 8, 2021).
- Irawan, C., et al. 2016. *Expression of biomarkers CXCR4, IL11-RA, TFF1, MLF1P in advanced breast cancer patients with bone metastatic: a diagnostic study*. *Acta Med Indones*, 48(26): 1-8.
- James, R. E., Baker, H. I., & Scanlon, P. W. (1972). The Roentgenologic Aspects of Metastatic Pheochromocytoma. *72nd Annual Meeting of The American Roentgen Ray Society*, 783–793.
- Jenny, C. 2005. ‘CHILDREN | Physical Abuse’. In *Encyclopedia of Forensic and Legal Medicine* (pp. 363–372). Elsevier. <https://doi.org/10.1016/B0-12-369399-3/00049-5>
- Jia, J., Zhang, W.-F., Liu, B., & Zhao, Y.-F. 2006. Pathological fracture of condyle from metastatic breast adenocarcinoma. *Oral Oncology Extra*, 42(3), 98–100. <https://doi.org/10.1016/j.ooe.2005.09.009>
- Kalogeropoulou, C., Karachaliou, A., & Zampakis, P. 2009. ‘Radiologic Evaluation Of Skeletal Metastases: Role Of Plain Radiographs And Computed Tomography’. In *Cancer Metastasis – Biology and Treatment Volume 12* (pp. 119–136). Springer. [https://doi.org/10.1007/978-1-4020-9819-2\\_6](https://doi.org/10.1007/978-1-4020-9819-2_6)

- Kampalath, R., & Paul, D. 2020. *What Is a Skeletal Survey?* [Online] on Verywell Health <https://www.verywellhealth.com/skeletal-survey-4685302> (Accessed on August 6, 2021)
- Karsenty, G. 1999. The genetic transformation of bone biology. *Genes & Development*, 13(23), 3037–3051. <https://doi.org/10.1101/gad.13.23.3037>
- Kaufhold, S., & Bonavida, B. 2014. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. *Journal of Experimental & Clinical Cancer Research*, 33(1), 62. <https://doi.org/10.1186/s13046-014-0062-0>
- Kemenkes RI. 2019. *Infodatin: Beban Kanker di Indonesia*. Pusat Data dan Informasi Kementerian Kesehatan RI.
- Koh, J., M. J. Kim. 2019. *Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage*. *Korean J Radiol*, 20(1):69-82. <https://doi.org/10.3348/kjr.2018.0231>
- Komite Penanggulangan Kanker Nasional. 2016. *Panduan Penatalaksanaan Kanker Payudara*. Jakarta: Kementerian Kesehatan RI
- Koo, M.M., Wagner, C. Von, Abel, G.A., Mcphail, S., Rubin, G.P. & Lyratzopoulos, G. 2017. *Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals : Evidence from a national audit of cancer diagnosis*. *Cancer Epidemiology*, 48:140–146. <https://doi.org/10.1016/j.canep.2017.04.010>
- Labellapansa, A., Muhimmah, I., & Indrayanti. 2013. *Klasifikasi Citra Imunohistokimia Sel Kanker Payudara HER2 Skore 1+ dan 3+*. Seminar Nasional Informatika Medis (SNIMed) IV, 24.
- Largillier, R., Ferrero, J.-M., Doyen, J., Barriere, J., Namer, M., Mari, V., Courdi, A., Hannoun-Levi, J. M., Ettore, F., Birtwisle-Peyrottes, I., Balu-Maestro, C., Marcy, P. Y., Raoust, I., Lallement, M., & Chamoirey, E. (2008). Prognostic factors in 1,038 women with metastatic breast cancer. *Annals of Oncology : Official Journal of the European Society for Medical Oncology*, 19(12), 2012–2019. <https://doi.org/10.1093/annonc/mdn424>
- Li, D., Peng, H., Qu, L., Sommar, P., Wang, A., Chu, T., Li, X., Bi, X., Liu, Q., Gallais S  rezal, I., Rollman, O., Lohcharoenkal, W., Zheng, X., Eliasson Angelstig, S., Gr  nler, J., Pivarcsi, A., Sonkoly, E., Catrina, S.-B., Xiao, C., Xu Land  n, N. (2021). miR-19a/b and miR-20a Promote Wound Healing by Regulating the Inflammatory Response of Keratinocytes. *Journal of Investigative Dermatology*, 141(3), 659–671. <https://doi.org/10.1016/j.jid.2020.06.037>
- Lin, P. 2018. ‘Multiple Myeloma and Other Plasma Cell Neoplasms’. In E. D. Hsi (Ed.), *Hematopathology* (3rd Edition, pp. 642–663). Elsevier.

<https://doi.org/10.1016/B978-0-323-47913-4.00021-5>

- Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. *Cancer and Metastasis Reviews*, 33(1), 231–269. <https://doi.org/10.1007/s10555-014-9498-0>
- Mohan, S., Sudarsa, I.W., Mahadewa, T. G. B., Manuaba, I. B. T. W., Winata, A., Saputra, H. 2016. *Hubungan Ekspresi Receptor Activator of Nuclear Factor-Kb Ligand Tinggi dan Subtipe Luminal pada Tumor Primer Sebagai Faktor Risiko Terjadinya Metastasis Tulang pada Pasien Kanker Payudara*.
- Munandar, A., & Supriana, N. 2010. *Metastasis Tulang: Pendekatan Diagnosis dan Tatalaksana Radioterapi*. *Radioterapi & Onkologi Indonesia*, 1(2): 67–72.
- Murphy, A., & Mudgal, P. 2019. *Skeletal survey*. [Online] on Radiopaedia. <https://radiopaedia.org/articles/skeletal-survey> (Accessed August 6, 2021)
- Nani, D. (2009). Analisis Faktor-Faktor yang Berhubungan dengan Kejadian Kanker Payudara di Rumah Sakit Pertamina Cilacap. *Jurnal Keperawatan Soedirman*, 4(2), 61–66. <https://doi.org/http://dx.doi.org/10.20884/1.jks.2009.4.2.224>
- Napitupulu, E., & Sekarutami, S. M. 2010. Metastasis Tulang: Patofisiologi. *Radioterapi & Onkologi Indonesia*, 1(2), 59–66.
- Nicolin, V., Bortul, R., Bareggi, R., Baldini, G., Martinelli, B., & Narducci, P. 2008. Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway. *Acta Histochemica*, 110(5), 388–396. <https://doi.org/10.1016/j.acthis.2007.12.002>
- Nishimura, R., Osako, T., Okumura, Y., Hayashi, M., Toyozumi, Y., & Arima, N. 2010. *Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer*. *Experimental and Therapeutic Medicine*, 1(5): 747–754. <https://doi.org/10.3892/etm.2010.133>
- National Center for Biotechnology Information. 2021. *NATI N-acetyltransferase 1 [Homo sapiens (human)]*. NCBI. <https://www.ncbi.nlm.nih.gov/gene/9> (Accessed 21.9.2021)
- O'Connor, S. M., & Lawton, T. J. 2015. Can Molecular Subtyping Be Used to Guide Metastatic Screening in Breast Cancer? *American Journal of Clinical Pathology*, 143(4), 468–470. <https://doi.org/10.1309/AJCPR3BFA2PHSNYD>
- O'Sullivan, G. J., Carty, F. L., & Cronin, C. G. 2015. Imaging of bone metastasis: An update. *World Journal of Radiology*, 7(8), 202–211. <https://doi.org/10.4329/wjr.v7.i8.202>
- Parkes, A., Clifton, K., Al-Awadhi, A., Oke, O., Warneke, C. L., Litton, J. K., &



- Hortobagyi, G. N. (2018). Characterization of bone only metastasis patients with respect to tumor subtypes. *Npj Breast Cancer*, 4(2). <https://doi.org/10.1038/s41523-018-0054-x>
- Purba, D. A. K. 2018. *Gambaran Lokasi Metastasis Berdasarkan Hasil Pemeriksaan Foto Toraks dan Ultrasonografi pada Penderita Kanker Payudara Sesuai Hasil Hispatologi di RSUP Haji Adam Malik Tahun 2015-2017*. Universitas Sumatera Utara.
- Rakasiwi, N., Setiawan, G., Aryana, I. 2019. *Karakteristik kanker payudara dengan metastasis tulang tahun 2015-2017 di RSUP Sanglah Denpasar*. JMU: 1-6
- Ramos-Vara, J. A. 2005. *Technical Aspects of Immunohistochemistry*. Veterinary Pathology, 42(4): 405–426. <https://doi.org/10.1354/vp.42-4-405>
- Regan, J. N., Mikesell, C., Reiken, S., Xu, H., Marks, A. R., Mohammad, K. S., Guise, T. A., & Waning, D. L. 2017. Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model. *Frontiers in Endocrinology*, 8(358), 1–8. <https://doi.org/10.3389/fendo.2017.00358>
- Robinson, M., Atmakusumah, T. D., Irawan, C., & Shatri, H. 2020. *Profil Imunohistokimia Pasien Kanker Payudara yang Mendapat Kemoterapi Berbasis Antrasiklin di RSUD Kota Bogor*. Jurnal Penyakit Dalam Indonesia, 6(4): 173–177. <https://doi.org/10.7454/jpdi.v6i4.345>
- Rummel, K., Benson, J., & Roller, L. (2021). Prostate adenocarcinoma with osteolytic metastases: Case report and review of the literature. *Radiology Case Reports*, 16(11), 3565–3568. <https://doi.org/10.1016/j.radcr.2021.08.056>
- Sabariani, R. R. 2010. Efektivitas Radiasi Teknik 3DCRT Dibanding dengan Teknik Multi-Field dan Teknik Plan Paralel Terhadap Volume Jaringan Sehat Sekitar Tumor pada Kasus Tumor Otak. *Radioterapi & Onkologi Indonesia*, 1(2), 54–58.
- Saika, K., & Sobue, T. (2009). Epidemiology of Breast Cancer in Japan and the US. *JMAJ*, 52(1), 39–44.
- Santhiadi, N. G. T., Sudarsa, I. W., & Mahadewa, T. G. B. 2019. High receptor activator of Nuclear Factor Kappa  $\beta$  (RANK) expression and luminal A subtype are associated with bone metastasis in patients with breast cancer. *Bali Medical Journal*, 8(3), 537–541. <https://doi.org/10.15562/bmj.v8i3.1573>
- Sastroasmoro, S. & Ismael, S. 2011. *Dasar-dasar metodologi penelitian klinis*. 4 ed. Jakarta: Sagung Seto.
- Shi, D., Bai, J., Chen, Y., Wang, X., Zhang, Y., & Liu, H. 2020. Predicting the incidence and prognosis of bone metastatic breast cancer: A SEER-based observational study. *BioMed Research International*, 2020.

<https://doi.org/10.1155/2020/1068202>

- Sihombing, M., & Sapardin, A. N. 2015. Faktor Risiko Tumor Payudara pada Perempuan Umur 25-65 Tahun di Lima Kelurahan Kecamatan Bogor Tengah. *Jurnal Kesehatan Reproduksi*, 5(3), 1–10. <https://doi.org/10.22435/kespro.v5i3.3895.175-184>
- Sirait, A. M., R., O., & L., I. 2009. Hubungan Kontrasepsi Pil dengan Tumor/Kanker Payudara di Indonesia. *Majalah Kedokteran Indonesia*, 59(8), 348–356.
- Soediro, R., Nugroho, R. S., Gondhowiardjo, S. A., Djoerban, Z., & Poetiray, E. D. C. 2010. *Karakteristik Subtipe Kanker Payudara Berdasarkan Status Hormonal dan Her-2*. Radioterapi & Onkologi Indonesia, 1(2): 43–47.
- Soeharno, H., Povegliano, L., & Choong, P.F. 2018. Multimodal Treatment of Bone Metastasis- A Surgical Perspective. *Front. Endocrinol*, 9: 518. doi: 10.3389/fendo.2018.00518
- Sohn, W.M., K. Han, M. Seo. 2016. *Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors*. Iran J Radiol. 13(4): 31-38. doi: 10.5812/iranjradiol.31386
- Soni, A., Ren, Z., Hameed, O., Chanda, D., Morgan, C. J., Siegal, G. P., & Wei, S. 2015. Breast Cancer Subtypes Predispose the Site of Distant Metastases. *American Journal of Clinical Pathology*, 143(4), 471–478. <https://doi.org/10.1309/AJCPYO5FSV3UPEXS>
- Stepp, M. W., Salazar-González, R. A., Hong, K. U., Doll, M. A., & Hein, D. W. 2019. N -Acetyltransferase 1 Knockout Elevates Acetyl Coenzyme A Levels and Reduces Anchorage-Independent Growth in Human Breast Cancer Cell Lines. *Journal of Oncology*, 2019, 1–11. <https://doi.org/10.1155/2019/3860426>
- Suparman, E., & Suparman, E. 2014. Peran Estrogen dan Progesteron terhadap Kanker Payudara. *Jurnal Biomedik*, 6(3), 141–148.
- Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, *et al.* 2017. *Risk factors and preventions of breast cancer*. Int J Biol Sci., 13(11): 87–97
- Tang, P. dan G.M. Tse. 2016. *Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update*. Arch Pathol Lab Med. 140 (8): 806–814. <https://doi.org/10.5858/arpa.2015-0133-RA>
- The Global Cancer Observatory. (2021). *Indonesia Fact Sheet*. [Available on] <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>
- Tulotta, C., Lefley, D. V., Freeman, K., Gregory, W. M., Hanby, A. M., Heath, P. R., Nutter, F., Wilkinson, J. M., Spicer-Hadlington, A. R., Liu, X., Bradbury,

- S. M. J., Hambley, L., Cookson, V., Allocca, G., Kruithof de Julio, M., Coleman, R. E., Brown, J. E., Holen, I., & Ottewell, P. D. (2019). Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. *Clinical Cancer Research*, 25(9), 2769–2782. <https://doi.org/10.1158/1078-0432.CCR-18-2202>
- Villanueva, M. T. (2015). LOX does some prepping. *Nature Reviews Cancer*, 15(7), 384–385. <https://doi.org/10.1038/nrc3976>
- Vinsentricia, A., Seno, D. S. H., & Bintang, M. (2015). In Silico Analysis of Curcuma longa Against PCAF Histone Acetyltransferase. *Current Biochemistry*, 2(2), 43–53.
- Wang, D., Para, M. F., Koletar, S. L., & Sadee, W. (2011). Human N-acetyltransferase 1 \*10 and \*11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. *Pharmacogenetics and Genomics*, 21(10), 652–664. <https://doi.org/10.1097/FPC.0b013e3283498ee9>
- Weizmann Institute of Science. (2021a). *IBSP Gene (Protein Coding)*. GeneCards. <https://www.genecards.org/cgi-bin/carddisp.pl?gene=IBSP> (Accessed 27.9.2021)
- Weizmann Institute of Science. (2021b). *NAT1 Gene (Protein Coding)*. GeneCards. <https://www.genecards.org/cgi-bin/carddisp.pl?gene=NAT1> (Accessed 21.9.2021)
- Wibawa, I. G. N. A. A. S., Suryawisesa, I. B., Widiana, I. K., & Setiawan, I. G. B. (2020). Hubungan antara platelet lymphocyte ratio (PLR) dengan sub tipe kanker payudara pada pasien kanker payudara di Rumah Sakit Umum Pusat Sanglah, Denpasar. *Intisari Sains Medis*, 11(3), 1475–1481. <https://doi.org/10.15562/ism.v11i3.834>
- Widyaningrum, R., Faisal, A., Mitrayana, M., Mudjosemedi, M., & Agustina, D.-. 2018. *Oral cancer imaging: the principles of interpretation on dental radiograph, CT, CBCT, MRI, and USG*. Majalah Kedokteran Gigi Indonesia, 4(1): 1–14. <https://doi.org/10.22146/majkedgiind.22050>
- Wiguna, N. I. P., & Manuaba, I. T. W. 2014. *Karakteristik Pemeriksaan Imunohistokimia pada Pasien Kanker Payudara di RSUP Sanglah Periode 2003-2012*. E-Jurnal Medika Udayana, 3(12): 1–13.
- Wijaya, I. G. C. P., & Manuaba, I. B. T. W. 2017. *Hubungan Sub tipe Imunohistokimia dengan Usia pada Pasien Kanker Payudara di RSUP Sanglah Kota Denpasar*. E-Jurnal Medika, 6(3): 1–5.
- Wu, K., Feng, J., Lyu, F., Xing, F., Sharma, S., Liu, Y., Wu, S.-Y., Zhao, D., Tyagi, A., Deshpande, R. P., Pei, X., Ruiz, M. G., Takahashi, H., Tsuzuki, S., Kimura, T., Mo, Y., Shiozawa, Y., Singh, R., & Watabe, K. (2021). Exosomal



miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. *Nature Communications*, 12(1), 5196. <https://doi.org/10.1038/s41467-021-25473-y>

Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017). Breast cancer subtypes predict the preferential site of distant metastases: A SEER based study. *Oncotarget*, 8(17), 27990–27996. <https://doi.org/10.18632/oncotarget.15856>

Yatulaili, F., Poedjomartono, B., & Dwidanarti, S. R. (2019). *Korelasi Subtipe Luminal Kanker Payudara dengan Tipe Lesi Metastasis Tulang Pada Pemeriksaan CT Scan*. Yogyakarta: Universitas Gadjah Mada

Yeeravalli, R., & Das, A. (2021). Molecular mediators of breast cancer metastasis. *Hematology/Oncology and Stem Cell Therapy*, 1–15. <https://doi.org/10.1016/j.hemonc.2021.02.002>

Yoneda, T., Tanaka, S. & Hata, K. 2013. *Role of RANKL/RANK in primary and secondary breast cancer*. *World J Orthop*, 4: 178-85

Zhao, C., Cai, X., Wang, Y., Wang, D., Wang, T., Gong, H., Sun, H., Jia, Q., Zhou, W., Wu, Z., Li, Z., & Xiao, J. (2020). NAT1 promotes osteolytic metastasis in luminal breast cancer by regulating the bone metastatic niche via NF- $\kappa$ B/IL-1B signaling pathway. *American Journal of Cancer Research*, 10(8), 2464–2479. <http://www.ncbi.nlm.nih.gov/pubmed/32905535>